You are here » Home » Companies » Company Overview » Dr Habeebullah Life Sciences Ltd

Dr Habeebullah Life Sciences Ltd.

BSE: 539267 Sector: Others
NSE: N.A. ISIN Code: INE579N01018
BSE 00:00 | 17 Apr Dr Habeebullah Life Sciences Ltd
NSE 05:30 | 01 Jan Dr Habeebullah Life Sciences Ltd
OPEN 54.15
PREVIOUS CLOSE 54.15
VOLUME 1000
52-Week high 75.50
52-Week low 27.95
P/E
Mkt Cap.(Rs cr) 80
Buy Price 54.15
Buy Qty 768.00
Sell Price 54.15
Sell Qty 41.00
OPEN 54.15
CLOSE 54.15
VOLUME 1000
52-Week high 75.50
52-Week low 27.95
P/E
Mkt Cap.(Rs cr) 80
Buy Price 54.15
Buy Qty 768.00
Sell Price 54.15
Sell Qty 41.00

Dr Habeebullah Life Sciences Ltd. (DRHABEEBULLAH) - Company History

Dr Habeebullah Life Sciences Limited was incorporated in January 251996. The Company is engaged into the business of research & experimental development on natural sciences and engineering including bio pharma and hospital services also.The Company changed its registered office from 1st Floor Jayavant House Azad Road Near CBT Bhandiwad Base Hubli - 580 020 (Karnataka) to 4-7-375/A Television Hotel Lane Esamia Bazar Hyderabad - 500 027 (Telangana) vide Regional Director (SER) Hyderabad order dated 31st March 2015.During the year 2015 the Order was passed by Regional Director (South East Region Hyderabad) dated 31st March 2015 relating to Change of Registered office of the company from one state (Hubli Karnataka) to another (Hyderabad Telangana).M/s. Mark Corporate Advisors Private Limited (Managers to Open Offer) informed the Company and the Stock Exchanges about the Share Purchase Agreement dated Wednesday 24 August 2016 entered by Mohammed Aejaz Habeeb (Acquirer 1) Syed Ameer Basha Paspala (Acquirer 2) and Kalidindi Krishnam Raju (Acquirer 3) with Arun Kumar Bhangadia Promoter of the Company (Seller) for acquisition of 2100000 Equity Shares representing 20.47% of the Emerging Voting Capital of the M/s. PC Products India Limited (Target Company). Further the Company in its Board Meeting held on Wednesday 24 August 2016 has decided and approved the following:1. To acquire not less than 51% stake in M/s. Krisani Bio Sciences Private Limited by way of Swapping of Shares from the Shareholders of M/s. Krisani Bio Sciences Private Limited. 2. Allotment of 4870606 Equity Shares on SWAP Basis to Kalidindi Krishnam Raju (Acquirer 3 and Shareholder of M/s. Krisani Bio Sciences Private Limited) and his relatives. Pursuant to SPA and Preferential Allotment the Acquirers have triggered the Open Offer as per SEBI (SAST) Regulations 2011 to acquire 2667300 Equity Shares of Rs. 10/- each of M/s. PC Products India Limited (Target Company) representing 26% of the Emerging Equity Share Capital / Voting Capital of the Target Company.During the year 2016-17 the Company has undergone re-structuring in terms of Capital Change in Promoters Shareholding and Change in Management of the Company. The details are as under:a) On Wednesday August 24 2016 the Board of Directors of the Company approved a Preferential Allotment of 4870606 Equity Shares (47.48% of Paid Up Capital) on SWAP Basis to specific Shareholders of Krisani Bio-Sciences Private Limited (83:100 i.e. for eEvery 100 Equity Shares held by the Shareholders of Krisani Bio-Sciences Private Limited 83 Equity Shares of PC Products India Limited were allotted). Out of 4870606 Equity Shares 2582130 Equity Shares were allotted to the present Promoters of the Company i.e. K. Krishnam Raju (Acquirer 3) and balance 2288476 Equity Shares to the PAC's of K. Krishnam Raju (PAC's: K. Sarada Vijaya Kumari (PAC 1) K. Nirusha (PAC 2) and P. Parvathi (PAC 3); pursuant to Section 62 and other applicable provisions of Companies Act 2013 and SEBI (ICDR) Regulations 2009. Pursuant to the Preferential Allotment Krisani Bio Sciences Private Limited has become the Subsidiary of the Company holding 51.30% of its Equity.b) On Wednesday 24th August 2016 Arun Kumar Bhangadia (Ex/Past Promoter of the Company) entered into a Share Purchase Agreement with the Acquirers to Open Offer and Present Promoters of the Company - Dr. Mohammed Aejaz Habeeb (Acquirer 1) Dr. Syed Ameer Basha Paspala (Acquirer 2) and K. Krishnam Raju (Acquirer 3) for Sale of 2100000 Equity Shares. Upon completion of the aforementioned Preferential Allotment of Equity Shares and pursuant to Share Purchase Agreement; Dr. Mohammed Aejaz Habeeb (Acquirer 1) Dr. Syed Ameer Basha Paspala (Acquirer 2) K. Krishnam Raju (Acquirer 3) Kalidindi Sarada Vijaya Kumari (PAC 1) K. Nirusha (PAC 2) and P. Parvathi (PAC 3) triggered Open Offer under Regulation 3(1) and 4 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations 2011 as amended from time to time.The Tendering Period of Open Offer was Tuesday 22nd November 2016 to Monday 05th December 2016. Post Open Offer the holding of New Promoters - Dr. Mohammed Aejaz Habeeb (Acquirer 1) Dr. Ameer Basha Paspala (Acquirer 2) K. Krishnam Raju (Acquirer 3) K. Sarada Vijaya Kumari (PAC 1) K. Nirusha (PAC 2) and P. Parvathi (PAC 3) is 7629030 Equity Shares (74.37% of Paid-Up Capital).Dr. Mohammed Aejaz Habeeb (Acquirer 1) Dr. Syed Ameer Basha Paspala (Acquirer 2) K. Krishnam Raju (Acquirer 3) K. Sarada Vijaya Kumari (PAC 1) K. Nirusha (PAC 2) and P. Parvathi (PAC 3) have also acquired control over the affairs and management of the Company w.e.f. Tuesday 27th December 2016 and were classified as New Promoters of the Company as per Regulation 31(A) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 and within the meaning definition of Promoter as defined in SEBI (Substantial Acquisition of Shares and Takeovers) Regulations 2011 as amended from time to time. Post Open Offer and as per the Share Purchase Agreement; the Ex/Past Promoter Arun Kumar Bhangadia was re-classified under Public Category with his balance Equity Shares - 826800 Equity Shares (8.06% of Paid Up Capital). During FY2016-17 under review the Company acquired one Subsidiary - Krisani Bio Sciences Private Limited India.From June 2017 the Company has only reportable segment i.e. Bio-Pharma Sector.During Financial year 2017-18 the Paid up Capital of the Company increased from Rs 102587060/- divided into 10258706 Equity Shares of Rs 10/- each to Rs 117587060/- divided into 11758706 Equity Shares of Rs 10/- each. The Company allotted 800000 Equity Shares to Non Resident Indians (NRIs) on Preferential Basis on 17 November 2017.The Company allotted 1000000 Convertible Equity Share Warrants to Promoters of the Company on Preferential Basis on 24 January 2018.The Company has allotted 2750000 Convertible Equity Share Warrants to Non-Promoters of the Company on Preferential Basis on 17 November 2017. Out of which 700000 Convertible Equity Share Warrants were converted into Equity Shares on 24 January 2018.The Company converted further 455000 Convertible Equity Share Warrants into Equity Shares on 04 May 2018 leading to increase in Paid up Capital to Rs 122137060 divided into 12213706 Equity Shares of Rs 10/- each.As per the SEBI Circular No IMD/FPIC/CIR/P/2018/61 dated 5 April 2018 the Central Depository Services (India) Limited (CDSL) was appointed as the Designated Depository for the purpose of monitoring the Foreign Investment Limits in the Company.As per SEBI Circular No SEBI/HO/CFD/DCR1/CIR/P/2018/85 dated 28 May 2018 the Central Depository Services (India) Limited (CDSL) was appointed as the Designated Depository for the purpose of System Driven Disclosures in Securities Market for the Company.The Name of the Company was changed from PC Products India Limited to Dr. Habeebullah Life Sciences Limited vide Fresh certificate of Incorporation obtained from Registrar of Companies Hyderabad Telangana State India dated 25 October 2017.The Company had entered into a Collaborative Agreement with its Subsidiary Krisani Bio Sciences Private Limited for further development of Wilson Disease Molecule on revenue sharing basis on 23 August 2017.The Company had entered into a Collaborative Agreement with its Subsidiary Krishna Bio Sciences Private Limited for further development of Wilson Disease Molecule on revenue sharing basis on 23 August 2017.The Company has terminated an Agreement entered with its Subsidiary Krisani Bio Sciences Private Limited on 17 November 2017 {Initially entered on dated 25 March 2017 for further development of NASH (Fatty Liver) Molecule}The Company has entered into a Collaborative Agreement with Centre for Liver Research And Diagnostics (CLRD) to use their land building equipment and other facilities to run business of Hospital Diagnostics Pharmacy Stem cell and other biotechnology laboratories on revenue sharing basis dated 27 May 2017.The Securities Exchange Board of India vide its Adjudication Order EAD-5/ SVKM /AO / 21/2017-18] dated 17 May 2017 had imposed a penalty of Rs 400000/- on the Company for non-compliance of provisions of Regulation 8(3) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations 1997 within the due date during the years 2004 to 2011 at Ahmedabad Stock Exchange Bangalore Stock Exchange and Madras Stock Exchange where its Equity Shares were listed. The Company has paid the penal amount of Rs 400000/- on Monday 29 May 2017 to Securities Exchange Board of India towards the Adjudication Order.The Company converted 455000 Convertible Equity Share Warrants into Equity Shares on 04 May 2018 and further converted 1595000 equity share warrants into equity shares on 26 March 2019 during the FY 2018-19.During FY 2018-19 the Paid up Capital of the Company increased from Rs 117587060/- divided into 11758706 Equity Shares of Rs 10/- each to Rs 138087060/- divided into 13808706 Equity Shares of Rs 10/- each.The Company converted further 1000000 Convertible Equity Share Warrants into Equity Shares on 14th June 2019 leading to increase in paid up capital to Rs. 148087060 divided into 14808706 Equity Shares of Rs 10/- each.